Press Releases
Leaders in pioneering cancer diagnostics and NGS target enrichment technologies join forces to accelerate access to advanced molecular diagnostics for cancer Excerpt from the Press Release: FREMONT, Calif. and TAIZHOU, China, July 30, 2025 (GLOBE NEWSWIRE) — Paragon Genomics, Inc., a global leader in target enrichment solutions for next-generation sequencing (NGS), and Genecast (Taizhou) Biotechnology…
Read More
Patent Strengthens International Protection for First-of-Its-Kind Immunopreventive Platform Expands Global IP Coverage in Markets with High Incidence of Breast Cancer Excerpt from the Press Release: SAN JOSE, Calif., July 30, 2025 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced…
Read More
Excerpt from the Press Release: NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain–(BUSINESS WIRE)–Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the refusal of the marketing authorization for pridopidine’s marketing authorization application for Huntington’s disease (HD). We are disappointed, but…
Read More
Excerpt from the Press Release: NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced results showing that implementing a blood-based pTau217 screening assay reduced Acumen’s overall clinical trial…
Read More
Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025 First Patient Dosed in 6E13 vg/kg Cohort 2 of RIDGE™-1 Phase 1b Clinical Trial of TN-401 for Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)…
Read More Potent TCR-mimetic CD3 T-cell engaging antibody targets peptide HLA complexes from TERT, a broadly expressed tumor antigen Preclinical studies demonstrate strong efficacy and a favorable safety profile Nomination expands Crossbow’s pipeline and reinforces the scalability of its T-Bolt™ platform to treat a wide range of cancers Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Crossbow Therapeutics,…
Read More Excerpt from the Press Release: NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the…
Read More Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Company’s Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager (TCE) targeting EGFR (epidermal growth factor receptor). VIR-5525 will be evaluated for the treatment of a variety of EGFR-expressing solid…
Read More Topline Readout Expected in Q3 2026- Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK-001, a highly…
Read More
Phase 1 clinical trial of ADI-001 in autoimmune diseases actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and SSc Preliminary clinical data from Phase 1 trial of ADI-001 in autoimmune diseases expected in 2H/2025 Excerpt from the Press Release: REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage…
Read More